Compare PBH & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PBH | IMNM |
|---|---|---|
| Founded | 1996 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 2.8B |
| IPO Year | 2004 | 2020 |
| Metric | PBH | IMNM |
|---|---|---|
| Price | $62.00 | $21.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 10 |
| Target Price | ★ $80.75 | $32.80 |
| AVG Volume (30 Days) | 358.7K | ★ 924.3K |
| Earning Date | 05-07-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 2.88 | ★ 51.40 |
| EPS | ★ 2.78 | N/A |
| Revenue | ★ $975,777,000.00 | $6,941,000.00 |
| Revenue This Year | N/A | $18.41 |
| Revenue Next Year | $2.15 | $863.23 |
| P/E Ratio | $23.33 | ★ N/A |
| Revenue Growth | ★ 36.77 | N/A |
| 52 Week Low | $57.25 | $5.15 |
| 52 Week High | $88.55 | $27.65 |
| Indicator | PBH | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 30.65 | 42.40 |
| Support Level | $60.75 | $18.98 |
| Resistance Level | $63.26 | $22.57 |
| Average True Range (ATR) | 1.81 | 1.10 |
| MACD | -0.82 | -0.09 |
| Stochastic Oscillator | 0.11 | 29.45 |
Prestige Consumer Healthcare is one of the largest pure-play over-the-counter healthcare providers. It has a diverse portfolio composed of leading brands in niche consumer health categories. Prestige's key brands include Clear Eyes (redness relief), Dramamine (motion sickness relief), Monistat (vaginal anti-fungal), and Summer's Eve (feminine hygiene), and many of its brands enjoy category leadership and recommendations from medical professionals. The firm mainly plays in North America where it generates roughly 85% of its total revenue, and the remaining sales come from Australia, New Zealand, and certain Asian markets.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.